1000 WINTER ST, SUITE 1200, WALTHAM, MA
Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis
Announce License Agreement Granting Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis
Enter into Obexelimab Funding Agreement for up to $300 Million
Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Material disclosure
Corporate Presentation June 2025 Enabling Patients with Autoimmune Diseases to Reimagine Life
Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Q2
Q1
FY 2024
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership